Epitalon slowed estrous aging and cut leukemia 6-fold in female SHR mice
Background
Aging-related genomic instability and declining reproductive neuroendocrine function are established biomarkers of biological aging in rodent models, yet no broadly accepted geroprotective agent exists for clinical or preclinical use. Spontaneous tumor incidence, particularly leukemia, rises steeply with age in outbred mouse strains, making lifespan studies in these models highly relevant to cancer-aging intersections. Epitalon — the synthetic tetrapeptide Ala-Glu-Asp-Gly — was developed as a pineal-derived peptide hypothesized to modulate neuroendocrine-immune aging pathways, providing a rationale for testing long-term subcutaneous administration across a full murine lifespan. Understanding whether such a peptide can simultaneously affect chromosomal integrity, reproductive aging, longevity metrics, and tumor development without toxicity is a central unanswered question in peptide geroscience.
Study Design
Female outbred Swiss-derived SHR mice (n = 54 per group) received subcutaneous injections of Epitalon 1.0 µg/mouse (~30–40 µg/kg) in 0.1 ml saline on 5 consecutive days every month starting at 3 months of age and continuing until natural death. Controls received 0.1 ml normal saline on the same schedule. Primary endpoints included mean and maximum lifespan, lifespan of the last 10% of survivors, estrous cycle function, chromosome aberration frequency in bone marrow cells, body weight, food consumption, and spontaneous tumor incidence including leukemia.
Results
Epitalon treatment did not alter food consumption, body weight, or mean lifespan relative to controls. However, it slowed the age-related switching-off of estrous function, indicating preserved reproductive neuroendocrine activity in treated animals. Chromosome aberrations in bone marrow cells were reduced by 17.1% (P < 0.05), reflecting improved genomic stability. The lifespan of the last 10% of survivors increased by 13.3% (P < 0.01), and maximum lifespan increased by 12.3% compared with controls.
Epitalon inhibited the development of spontaneous leukemia by 6.0-fold compared with the control group, despite having no effect on total spontaneous tumor incidence.
The combined longevity and genomic data support classification of Epitalon as a geroprotector, and no adverse safety signals were noted across long-term monthly administration.
Key Findings
- Chromosome aberrations in bone marrow reduced by 17.1% (P < 0.05)
- Last-10%-survivor lifespan increased by 13.3% (P < 0.01)
- Maximum lifespan increased by 12.3% vs. controls
- Spontaneous leukemia incidence inhibited 6.0-fold vs. controls
- No effect on mean lifespan, body weight, food consumption, or total tumor incidence
Why It Matters
The 6-fold suppression of spontaneous leukemia is among the most striking single-compound anti-leukemia effects reported in a full-lifespan mouse study, and it arrives alongside meaningful longevity and genomic-stability data — a rare trifecta in peptide aging research. For clinicians and researchers considering Epitalon protocols, the monthly pulsed dosing schedule (5 consecutive days/month) used here provides a concrete, well-tolerated regimen template directly supported by a full-lifespan safety dataset. Long-term subcutaneous administration appears safe in this model with no body-weight or food-intake disruption, strengthening the case for extended human-analogous regimens. Translation to humans remains speculative; the preserved estrous function finding hints at neuroendocrine mechanisms worth exploring in perimenopausal or immunosenescence contexts.
TitrateLab articles covering Epitalon
Written by TitrateLab, separately from the study summarized above.
